Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06534671 · ClinicalTrials.gov registry record · Phase 4
Diltiazem in Jervell and Lange-Nielsen Syndrome
A Phase 4 study of Jervell and Lange Nielsen Syndrome, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT06534671 is a Phase 4 study of Jervell and Lange Nielsen Syndrome that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 1 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06534671, a Phase 4 study of Jervell and Lange Nielsen Syndrome, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the effect of diltiazem, a calcium channel blocking drug, on the QT interval in patients with Jervell and Lange-Nielsen syndrome. This will be a single IV dose and acute effects (within minutes) will be observed.
Conditions Studied
Interventions
- DRUG diltiazem
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2024-10-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06534671
The ClinicalTrials.gov registry entry for NCT06534671 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Jervell and Lange Nielsen Syndrome appearing as the primary indexed condition, and to 1 intervention - of which diltiazem is the first listed.
NCT06534671 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT06534671 about?
NCT06534671 is a clinical study titled "Diltiazem in Jervell and Lange-Nielsen Syndrome". This study will test the effect of diltiazem, a calcium channel blocking drug, on the QT interval in patients with Jervell and Lange-Nielsen syndrome. This will be a single IV dose and acute effects (within minutes) will be observed.
What is the current status of trial NCT06534671?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2024-10-16. Estimated completion is 2024-10-23.
What conditions does trial NCT06534671 study?
This clinical trial studies the following conditions: Jervell and Lange Nielsen Syndrome.
What interventions are being tested in trial NCT06534671?
The interventions under investigation include: diltiazem (DRUG).
Who is sponsoring clinical trial NCT06534671?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06534671 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.